Research programme: controlled-release therapeutics - Camurus

Drug Profile

Research programme: controlled-release therapeutics - Camurus

Alternative Names: CAM 2041; CAM 2046; CAM 2047; CAM 2048

Latest Information Update: 28 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camurus
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Diabetes mellitus; Inflammation; Pain; Postoperative pain

Most Recent Events

  • 28 Nov 2016 Camurus files a clinical trial application in Sweden for Postoperative pain
  • 31 Dec 2015 Preclinical trials in Cancer in Sweden (unspecified route) before December 2015
  • 31 Dec 2015 Preclinical trials in Diabetes mellitus in Sweden (unspecified route) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top